📖➡️The GCA story continues with new data from a Phase 3 trial of a JAKi, sponsored by AbbVie Medical Affairs + Health Impact. 🔥 Hot off the press from ACR 2025, hear Dr. Dua & Dr. Boone discuss the latest data in GCA. https://t.co/Wuu7xe5Xbl https://t.co/qj4xnzAjpy

Treating During Pregnancy (11.14.2025) | RheumNow https://t.co/sTv7O6YcnA https://t.co/KT0qGFJu0O

RNL 25 Replay: Rheumatoid Arthritis Enjoy these excerpts from the RNL 2025 meeting, and join us for RNL 2026 in Dallas, TX - registration is now open! Visit https://t.co/o78Pc8LPsQ for complete details https://t.co/10AWx98UAk https://t.co/16FdwSu9he

Postmenopausal women on estrogen hormone therapy (HT) had a modest incr risk (HR 1.33; 1.32-1.35; P < .001). of a new autoimmune Dz over next 5-10 yrs (vs those not on HT) TriNetX study of 889,413 HT vs 2,6 mill (not HT) - 6.7% vs 5.3% developed autoimmune dz at 5 yrs. https://t.co/fsi32XIzLe

Retrospective cohort study adult RA patients shows that TRIPLE Positivity (RF + /ACPA + /ANA +) was consistently associated with higher disease activity at baseline and 12 months of follow-up and lower rates of sustained remission compared to RF + /ACPA + /ANA- https://t.co/mLRCzczqXH

Can EMR Treatment Suggestions Improve Decision Making? In a new study, researchers from Northwestern University and the University of Sydney identified a “sweet spot” in clinical decision-making. By presenting just the right number of treatment alternatives in the EHR system, https://t.co/X0eHDIk3Uw

Hospital Mortality in Dermatomyositis A cohort study reveals that hospitalized patients with dermatomyositis have a higher in-hospital mortality rate in the presence of active rash, interstitial lung disease, and an elevated neutrophil-to-lymphocyte ratio at admission. https://t.co/6WIFVJT9w7

In 2024, 77 pts referred to Rheum for possible PMR were ultimately Dx w/ B19 viral infx. 96% had arthralgia & 7% had PMR-like features (5/5 w/ BL shoulder/neck. prolonged AM stiff, fever & Hi CRP/ESR - none had hip pain. 4/5 were male, w/ mean age of 55 yrs. None were RF/CCP+ https://t.co/SsLVEyL8X8

IL-23 Blockade Goes Oral A new player is entering the IL-23 arena — and it’s a tablet! Icotrokinra (ICO), a first-in-class peptide that binds and blocks the IL-23R, is showing encouraging efficacy and safety across a range of psoriasis (PSO) and psoriatic disease (PsD) studies. https://t.co/fYXULrMD16

+ANA's are common in pregnancy. Study of 2159 Chinese 1st trimester pregnant women found ANAs positivity in 14.7 % (1:100 most common titer; speckled most common pattern). ANA+ assoc w/ smoking, age 30-34 yrs, multiparity, thyroid Dz & hypertension https://t.co/mRQGajVe3g https://t.co/DqE1KC4Kgo

Learning just got smarter. Every week, RheumIQ challenges you with a quick quiz on current rheumatology updates. 💡 Educational 🎯 Evidence-based 🧠 Addictive (in a good way) Try it now and level up your clinical knowledge: https://t.co/n6xlBFMPLI https://t.co/RHci93G46T